Science & Technology
Development and in vivo validation of a machine learning platform to predict ototoxic potential of pharmaceuticals
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41DC021390-01
Award Ceiling
$276K
Award Floor
$276K
Close Date
Apr 30, 2025
Total Funding
$276K
Expected Awards
1
Posted Date
Aug 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R41DC021390-01
Description
STTR Phase Phase I award: "Development and in vivo validation of a machine learning platform to predict ototoxic potential of pharmaceuticals" awarded to REWIRE NEUROSCIENCE LLC in PORTLAND, Oregon. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $275,737. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, HUBZone businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.